Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects

Deucravacitinib is a novel, oral, selective inhibitor of the intracellular signaling kinase tyrosine kinase 2. This phase 1, randomized, partially double‐blind, 4‐period crossover study in healthy adults was conducted to determine whether deucravacitinib 12 mg (therapeutic dose) or 36 mg (suprathera...

Descripción completa

Detalles Bibliográficos
Autores principales: Chimalakonda, Anjaneya, Singhal, Shalabh, Darbenzio, Raymond, Dockens, Randy, Marchisin, David, Banerjee, Subhashis, Girgis, Ihab G., Throup, John, He, Bing, Aras, Urvi, Murthy, Bindu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306920/
https://www.ncbi.nlm.nih.gov/pubmed/35182043
http://dx.doi.org/10.1002/cpdd.1056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306920/
https://www.ncbi.nlm.nih.gov/pubmed/35182043
http://dx.doi.org/10.1002/cpdd.1056

Ejemplares similares